Hydroxychloroquine is Proven to Decrease the Viral Load of COVID-19

Effect of hydroxychloroquine on COVID-19
Effect of Hydroxychloroquine on COVID-19
April 15, 2020
classification of impurities in pharmaceutical drug products
Classification of Pharmaceutical Drug Impurities
April 29, 2020
Hydroxychloroquine is proven to decrease the viral load of COVID-19

Hydroxychloroquine, a derivative of Chloroquine, has been used for years in the treatment of malaria. The drug is also known to block the entry of many viruses into cells. A small clinical trial has revealed it to be effective in reducing viral loads in COVID-19 patients.

Enveloped viruses enter into a host, eventually fusing their viral genetic code with a healthy cell causing it to release viral genome into the cytoplasm. In many cases, after the virus particles have bound with the cell surface receptors, they are taken into cells via the endocytic pathway. As these vesicles move toward the nucleus, their pH drops, which catalyzes the fusion of viral and cell membranes. When cells are treated with chloroquine the pH of the endosome is elevated, which prevents fusion and blocks viral infection. The reproduction of many viruses is known to be inhibited by Chloroquine and Hydroxychlroquine.

Recently reproduction of the newly emerged SARS-CoV-2 in cells was found to be inhibited by Chloroquine. Consequently, a derivative of the drug, Hydroxychloroquine (a less toxic derivative) has been tested on patients affected with COVID-19. The results of a clinical study conducted in Marseille, France, to evaluate efficacy of hydroxychloroquine in treatment of COVID-19 were released on 18 March 2020. Patients included in the study were all over 12 years old and had a laboratory-confirmed infection with SARS-CoV-2. They received 600 mg of Hydroxychloroquine, daily, for ten days. Viral loads in the nasopharyngeal wash were measured daily.

The study was conducted on twenty patients having received treatment and 16 were untreated controls. By day 6 of the study, 70% of the treated patients, no longer harbored the virus as determined by RT-PCR, compared to 12.5% of the controls. The combination of Hydroxychloroquine plus Azithromycin was more effective in clearing the virus than Hydroxychloroquine alone.

Available Hydroxychloroquine impurities at Veeprho

Hydroxychloroquine EP Impurity A

CAS No:          1449223-88-4

Mol. Formula:  C18H26ClN3O2

Mol. Weight:    351.87

Hydroxychloroquine EP Impurity B

CAS No:         103152-84-7

Mol. Formula:  C18H25ClN3NaO4S

Mol. Weight:    437.92

Hydroxychloroquine EP Impurity C

CAS No:          4298-15-1

Mol. Formula:  C16H22ClN3O

Mol. Weight:    307.82

Hydroxychloroquine EP Impurity D

CAS No:         1476-52-4

Mol. Formula:  C16H22ClN3

Mol. Weight:    291.82

Hydroxychloroquine EP Impurity E

CAS No:          10500-64-8

Mol. Formula:  C14H17ClN2O

Mol. Weight:     264.75

Hydroxychloroquine EP Impurity F

CAS No:          6281-58-9

Mol. Formula:  C14H15ClN2

Mol. Weight:     246.74

Hydroxychloroquine O-Acetate

CAS No:         47493-14-1

Mol. Formula: C20H28ClN3O2

Mol. Weight:    377.92

To know more about Hydroxychloroquine read our previous blog about Effect Hydroxychloroquine on COVID-19

Leave a Reply

Your email address will not be published. Required fields are marked *

Social Share Buttons and Icons powered by Ultimatelysocial